Addendum
Idecabtagene vicleucel (multiple myeloma, at least 2 prior therapies) – Addendum to Project A24-35
Report documents
-
Addendum
Idecabtagene vicleucel (multiple myeloma, at least 2 prior therapies) – Addendum to Project A24-35
Dossier assessment
Indication:
Adults with relapsed and refractory multiple myeloma who have received prior therapies and have demonstrated disease progression on the last therapy; pretreatment includes an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody
Result of dossier assessment:
- Patients with 2 to 3 prior therapies: Unchanged after addendum: added benefit not proven
- Patients with at least 4 prior therapies: Unchanged after addendum: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2024-09-19 A G-BA decision was published.
Project details
- Project no.
- A24-81
- Commission
- Commission awarded on 06.08.2024 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A24-81_en
Connected Projects
-
Dossier assessment
Idecabtagene vicleucel (multiple myeloma, at least 2 prior therapies) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed